Skip to content

Insider · CIK 0001356256

Scott Dunseth Myers

director

Files at DVAX (DYNAVAX TECHNOLOGIES CORP), ZNTL (Zentalis Pharmaceuticals, Inc.). First filing Apr 30, 2025, latest Aug 25, 2025.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
2 / 0
$70k bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

ZNTL: Zentalis Pharmaceuticals, Inc.

ZNTLOct 9, 2026 · close 2.64

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
24Weak
DVAXbuy
DYNAVAX TECHNOLOGIES CORP
$41k
3,800 shares
+12%-
31Weak
ZNTLbuy
Zentalis Pharmaceuticals, Inc.
$29k
21,000 shares
+8%+37% from low-67% from high

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Aug 22, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
POpen-market purchase
Common Stock
+3,800$10.82$41k35,004Aug 25, 2025
Jun 17, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
AGrant or award
Common Stock
+57,603$0.00$0338,795Jun 18, 2025
Jun 11, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
AGrant or award
Common Stock
+5,758$0.00$031,204Jun 13, 2025
Jun 11, 2025DVAX
DYNAVAX TECHNOLOGIES CORP
AGrant or award
Stock Option (Right to Buy)derivative
+28,500$0.00$028,500Jun 13, 2025
Apr 30, 2025ZNTL
Zentalis Pharmaceuticals, Inc.
POpen-market purchase
Common Stock
+21,000$1.40$29k281,192Apr 30, 2025
Nov 13, 2024ZNTL
Zentalis Pharmaceuticals, Inc.
AGrant or award
Common Stock
+260,192$0.00$0260,192Nov 13, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Scott Dunseth Myers: insider trades and track record | InsiderTell